Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?

[1]  K. Anstrom,et al.  NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. , 2019, JACC. Heart failure.

[2]  小室 一成,et al.  NT-proBNP , 2009, Springer Reference Medizin.

[3]  J. Januzzi,et al.  Established and Emerging Roles of Biomarkers in Heart Failure , 2018, Circulation research.

[4]  Thomas J. Wang,et al.  Effect of NT-proBNP-Guided Therapy on All-Cause Mortality in Chronic Heart Failure With Reduced Ejection Fraction. , 2018, Journal of the American College of Cardiology.

[5]  W. Kraus,et al.  Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. , 2017, JACC. Heart failure.

[6]  K. Anstrom,et al.  Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial , 2017, JAMA.

[7]  K. Anstrom,et al.  Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial , 2017, JAMA.

[8]  Leonard A Kaminsky,et al.  Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign A Scientific Statement From the American Heart Association , 2016, Circulation.

[9]  P. Lambiase,et al.  Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification. , 2016, The American journal of cardiology.

[10]  K. Anstrom,et al.  Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure , 2016, Circulation. Heart failure.

[11]  Jacob P. Kelly,et al.  Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. , 2016, Journal of the American College of Cardiology.

[12]  E. Braunwald,et al.  Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). , 2015, JACC. Heart failure.

[13]  Svati H Shah,et al.  Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. , 2015, JACC. Heart failure.

[14]  W. Kraus,et al.  Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. , 2014, JACC. Heart failure.

[15]  Thomas J. Wang,et al.  Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. , 2014, JACC. Heart failure.

[16]  W. Kraus,et al.  Soluble ST2 in Ambulatory Patients With Heart Failure: Association With Functional Capacity and Long-Term Outcomes , 2013, Circulation. Heart failure.

[17]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[18]  E. Braunwald,et al.  PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. , 2012, Circulation. Heart failure.

[19]  W. Kraus,et al.  Modest Increase in Peak VO2 Is Related to Better Clinical Outcomes in Chronic Heart Failure Patients: Results From Heart Failure and a Controlled Trial to Investigate Outcomes of Exercise Training , 2012, Circulation. Heart failure.

[20]  P. Harst,et al.  The fibrosis marker galectin‐3 and outcome in the general population , 2012, Journal of internal medicine.

[21]  James D. Thomas,et al.  Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. , 2011, The American journal of cardiology.

[22]  Ross Arena,et al.  Cardiopulmonary exercise testing in the clinical evaluation of patients with heart and lung disease. , 2011, Circulation.

[23]  J. Cohn,et al.  Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial , 2010, Circulation.

[24]  M. V. Chávarri,et al.  La monitorización de ST2 soluble proporciona una estratificación del riesgo adicional en pacientes ambulatorios con insuficiencia cardiaca descompensada , 2010 .

[25]  R. Wachter,et al.  The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction , 2010, European journal of heart failure.

[26]  Ashley M. Miller,et al.  Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. , 2010, Journal of the American College of Cardiology.

[27]  Yasuo Ohashi,et al.  Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. , 2009, JAMA.

[28]  W. Kraus,et al.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.

[29]  Peter Buser,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[30]  J. Myers,et al.  B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure. , 2007, International journal of cardiology.

[31]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[32]  U. Janssens,et al.  The value of cardiopulmonary exercise testing and brain natriuretic peptide plasma levels in predicting the prognosis of patients with chronic heart failure. , 2006, European journal of internal medicine.

[33]  H. Drexler,et al.  The Transforming Growth Factor-&bgr; Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury , 2006 .

[34]  T. Hewett,et al.  GDF15/MIC-1 Functions As a Protective and Antihypertrophic Factor Released From the Myocardium in Association With SMAD Protein Activation , 2006, Circulation research.

[35]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[36]  U. Janssens,et al.  brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[37]  M. Vogeser,et al.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[38]  L. Tavazzi,et al.  Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? , 2001, European heart journal.

[39]  W. D. Fairlie,et al.  The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. , 2000, The Journal of clinical endocrinology and metabolism.

[40]  William J. Rogers,et al.  Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction , 1993 .

[41]  J R Wilson,et al.  Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure , 1991, Circulation.